Pfizer (PFE) Gets Fast Track Designation for NASH Therapy

Pfizer PFE recently announced that the FDA has granted Fast Track designation to its investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.